On November 27, Guangdong Hybribio Biotech Co., Ltd. (300639) announced that its wholly-owned subsidiary, Chaozhou Hybribio Biochemical Co., Ltd., has obtained an updated Medical Device Production License issued by the Guangdong Medical Products Administration.

The license modification primarily expands the production scope to include: - Class III 6840 in vitro diagnostic reagents - Class II 18 obstetrics/gynecology, assisted reproductive, and contraceptive devices - Class II 22 clinical laboratory instruments The license, numbered Yue-SFDA-MDP-20041040, remains valid until January 8, 2029.

For the first three quarters of 2025, Hybribio Biotech reported revenue of RMB 486 million with a net loss attributable to shareholders of RMB 128 million.